title: Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis.
abstract: The S100B protein is associated with brain damage and a breached blood-brain barrier. A previous pilot study showed that high serum levels of S100B are associated with shorter survival in glioma patients. The aim of our study was to assess the prognostic value in terms of survival and longitudinal dynamics of serum S100B for patients with newly diagnosed and recurrent glioma. We obtained blood samples from patients with newly diagnosed and recurrent glioma before the start (baseline) and at fixed time-points during temozolomide chemotherapy. S100B-data were dichotomized according to the upper limit of the reference value of 0.1 μg/L. Overall survival (OS) was estimated with Kaplan-Meier curves and groups were compared with the log rank analysis. To correct for potential confounders a Cox regression analysis was used. We included 86 patients with newly-diagnosed and 27 patients with recurrent glioma. Most patients in both groups had baseline serum levels within normal limits. In the newly diagnosed patients we found no significant difference in OS between the group of patients with S100B levels >0.1 μg/L at baseline compared to those with <0.1 μg/L. In the patients with recurrent glioma we found a significantly shorter OS for patients with raised levels. In both groups, S100B values did not change significantly throughout the course of the disease. Serum S100B levels do not seem to have prognostic value in newly diagnosed glioma patients. In recurrent glioma patients S100B might be of value in terms of prognostication of survival.
authors.affiliation: Department of Neurology, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
authors.forename: F K
authors.initials: FK
authors.lastname: Holla
authors.affiliation: Department of Neurology, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands. tj.postma@vumc.nl.
authors.forename: T J
authors.initials: TJ
authors.lastname: Postma
authors.affiliation: Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands.
authors.forename: M A
authors.initials: MA
authors.lastname: Blankenstein
authors.affiliation: Department of Neurology, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
authors.forename: T J M
authors.initials: TJM
authors.lastname: van Mierlo
authors.affiliation: Department of Neurology, Medical Center Haaglanden, The Hague, The Netherlands.
authors.forename: M J
authors.initials: MJ
authors.lastname: Vos
authors.affiliation: Department of Neurology, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
authors.forename: E M
authors.initials: EM
authors.lastname: Sizoo
authors.affiliation: Department of Neurology, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: de Groot
authors.affiliation: Department of Neurology, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.|Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands.
authors.forename: B M J
authors.initials: BMJ
authors.lastname: Uitdehaag
authors.affiliation: Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
authors.forename: J
authors.initials: J
authors.lastname: Buter
authors.affiliation: Medical Psychology, VU University Medical Center, Amsterdam, The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: Klein
authors.affiliation: Department of Neurology, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
authors.forename: J C
authors.initials: JC
authors.lastname: Reijneveld
authors.affiliation: Department of Neurology, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
authors.forename: J J
authors.initials: JJ
authors.lastname: Heimans
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000097:blood* / Q000188:drug therapy; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005910:Glioma / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism; D012189:Retrospective Studies; D009418:S100 Proteins / Q000097:blood*; D018709:Statistics, Nonparametric; D000077204:Temozolomide; D055815:Young Adult
chemical_list: D018906:Antineoplastic Agents, Alkylating; D009418:S100 Proteins; D003606:Dacarbazine; D000077204:Temozolomide
keywords: Chemotherapy; Glioma; Prognosis; S100B; Survival